Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/4586
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lindgren, P | - |
dc.contributor.author | Buxton, MJ | - |
dc.contributor.author | Kahan, T | - |
dc.contributor.author | Poulter, NR | - |
dc.contributor.author | Dahlof, B | - |
dc.contributor.author | Sever, PS | - |
dc.contributor.author | Wedel, H | - |
dc.contributor.author | Jönsson, B | - |
dc.date.accessioned | 2010-11-22T13:48:23Z | - |
dc.date.available | 2010-11-22T13:48:23Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Heart 94: e4, 2008 | en_US |
dc.identifier.issn | 1355-6037 | - |
dc.identifier.uri | http://heart.bmj.com/content/94/2/e4.full | en |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/4586 | - |
dc.description | Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society All rights reserved. | - |
dc.description.abstract | Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.Setting: Primary care.Patients: Patients with moderate hypertension and three or more additional risk factors.Interventions: Amlodipine 5-10 mg with perindopril 4 8 mg added as needed or atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as neededMain outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.Results: In the UK, the cost to avoid one cardiovascular event or procedure would be (sic)18 965, and the cost to gain one quality-adjusted life-year would be (sic)21 875. The corresponding figures for Sweden were (sic)13 210 and (sic) 856.Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare's Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol- based regimen in the population studied. | en_US |
dc.description.sponsorship | The study was supported by the principal funding source, Pfizer, New York, USA | en_US |
dc.language.iso | en | en_US |
dc.publisher | British Medical Journals Publishing Group Ltd & British Cardiovascular Society | en_US |
dc.relation.ispartof | The Health Economics Research Group | - |
dc.subject | Hypertension | en_US |
dc.subject | Primary prevention | en_US |
dc.subject | Amlodipine | en_US |
dc.subject | Atenolol | en_US |
dc.subject | Cost-effectiveness | en_US |
dc.title | Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen | en_US |
dc.type | Research Paper | en_US |
dc.identifier.doi | http://dx.doi.org/10.1136/hrt.2007.127217 | - |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 108.91 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.